SYDNEY, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN)

Graham Kelly PhD, CEO & Chairman attended the Rodman &Renshaw 16th Annual Global Investment Conference where he wasinterviewed by Ed Kershen, providing an overview andhistory of Novogen Ltd. and CanTx Inc., including growth prospectsbrought about by new and unique technologies of Novogen Ltd andCanTx Inc. Novogen and CanTx new technologies as Dr Kelly explainshave the potential to become the "go to" drugs for first linetherapy in particular cancers.

Please follow the link; 

About Novogen Limited

Novogen is a public, Australian drug-development company whoseshares trade on both the Australian Securities Exchange ('NRT') andNASDAQ ('NVGN'). The Novogen Group includes a New Haven CT - basedjoint venture company, CanTx Inc, with Yale University.

Novogen has two main drug technology platforms:super-benzopyrans (SBPs) and anti- tropomyosins (ATMs). SBPcompounds have been created to kill the full range of cells withina tumor, but particularly the cancer stem cells. The ATM compoundstarget the microfilament component of the cancer cell and when usedin conjunction with standard anti- microtubular drugs, result incomprehensive and fatal destruction of the cancer cell'scytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites,prostate cancer, neural cancers (glioblastoma, neuroblastoma) andmelanoma are the key clinical indications being pursued, with theultimate objective of employing both technologies as a unifiedapproach to first-line therapy.

About CanTx

CanTx Inc is a private biotechnology company based in New Haven,Connecticut, and established as a joint venture between Novogen andYale University. CanTx is dedicated to the development ofanti-cancer drugs for the treatment of ovarian cancer.

Further information is available on the Company's website, And
CONTACT: Corporate Contact         Executive Chairman & CEO Novogen Group         +61 (0) 2 9472 4100                  Media Enquiries         Operations Manager         +61 (0) 2 9472 4111                  Investors Enquiries         Executive Chairman & CEO         Novogen Group         +61 (0) 2 9472 4100